Potential Chitin Synthesis Inhibitors
-(2,6-Difluorobenzoyl)-3-(2-alkyl-3-oxopyridazin-4-yl)ureas 3a–3h
783
1
3
A solution of 0.48 g 2,6-difluorobenzoyl isocyanate (2.6mmol) in 5 cm dry toluene was added to a
3
stirred solution of 2.5mmol 2-alkyl-4-amino-3(2H)-pyridazinones 2a–2h in 5 cm dry toluene. The
mixture was stirred overnight at room temperature, then the solvent was removed by evaporation under
ꢁ
reduced pressure. The residue was chromatographed on a silica-gel column (petroleum ether (60–90 C)
ethyl acetate 4=1 to 2=1) to afford the desired product.
1
-(2,6-Difluorobenzoyl)-3-(2-methyl-3-oxopyridazin-4-yl]urea (3a, C H F N O )
13 10 2 4 3
ꢁ
1
Yield 58%; light yellow solid; mp 198–200 C; H NMR (500MHz, CDCl ): ꢀ ¼ 3.83 (s, CH ),
3
3
7
8
.02–7.06 (m, ArH), 7.49–7.55 (m, ArH), 7.73 (d, J ¼ 4.68Hz, PyH), 7.86 (d, J ¼ 4.61 Hz, PyH),
ꢂ1
.70 (s, NH), 11.37 (s, NH) ppm; IR (KBr): ꢁꢀ ¼ 3400, 3120, 1730, 1710, 1650 cm ; MS (70eV):
þ
3
m=z(%) ¼ 308 (M , 6), 165 (13), 141 (100), 113 (19); HRMS: calcd for C H F N O 308.0720,
1
3 10 2 4 3
1
found 308.0731; C NMR (125 MHz, DMSO-d ): ꢀ ¼ 39.7, 111.9, 112.9, 113.2, 135.4, 137.7, 150.1,
6
1
55.5, 157.8, 159.8, 162.2 ppm.
1
-(2,6-Difluorobenzoyl)-3-(2-ethyl-3-oxopyridazin-4-yl)urea (3b, C H F N O )
4 12 2 4 3
1
ꢁ
1
Yield 63%; light yellow solid; mp 217–218 C; H NMR (500 MHz, CDCl ): ꢀ ¼ 1.39
3
(
(
t, J ¼ 7.12 Hz, CH ), 4.26 (q, J ¼ 7.02 Hz, CH ), 7.02–7.05 (m, ArH), 7.49–7.55 (m, ArH), 7.74
3
2
d, J ¼ 4.59 Hz, PyH), 7.78 (d, J ¼ 4.64 Hz, PyH), 9.09 (s, NH), 11.38 (s, NH) ppm; IR (KBr):
ꢂ1
þ
ꢁ
ꢀ¼ 3420, 3220, 1750, 1700, 1660 cm ; MS (70 eV): m=z(%) ¼ 322 (M , 11), 165 (24), 141 (100),
1
3
1
37 (40), 113 (27); HRMS: calcd for C H F N O 322.0877, found 322.0860; C NMR
14 12 2 4 3
(
125 MHz, DMSO-d ): ꢀ ¼ 13.4, 46.9, 111.7, 112.9, 113.1, 135.5, 138.0, 150.0, 155.1, 157.8,
6
1
59.8, 162.2 ppm.
1
-(2,6-Difluorobenzoyl)-3-(2-propyl-3-oxopyridazin-4-yl)urea (3c, C H F N O )
1
5 14 2 4 3
ꢁ
1
Yield 62%; white solid; mp 170–171 C; H NMR (500 MHz, CDCl ): ꢀ ¼ 0.96 (t, J ¼ 7.41 Hz,
3
CH ), 1.82–1.88 (m, CH ), 4.15 (q, J ¼ 7.34 Hz, CH ), 7.02–7.05 (m, ArH), 7.49–7.55 (m, ArH),
3
2
2
7
.74 (d, J ¼ 4.69 Hz, PyH), 7.81 (d, J ¼ 4.69 Hz, PyH), 8.81 (s, NH), 11.38 (s, NH) ppm; IR (KBr):
ꢂ1
þ
ꢁ
ꢀ¼ 3450, 3180, 1750, 1710, 1680 cm ; MS (70 eV): m=z(%) ¼ 336 (M , 3), 157 (13), 141 (100),
1
3
1
13 (20); HRMS: calcd for C H F N O 336.1034, found 336.1036; C NMR (125 MHz,
15 14 2 4 3
DMSO-d ): ꢀ ¼ 10.9, 21.3, 53.1, 111.7, 112.9, 113.1, 135.6, 137.8, 150.1, 155.3, 157.8, 159.8,
6
1
62.2 ppm.
1
-(2,6-Difluorobenzoyl)-3-(2-n-butyl-3-oxopyridazin-4-yl)urea (3d, C H F N O )
1
6 16 2 4 3
ꢁ
1
Yield 57%; white solid; mp 217–218 C; H NMR (500MHz, CDCl ): ꢀ ¼ 0.89 (t, J ¼ 7.33 Hz, CH ),
3
3
1
.24–1.88 (m, CH ), 1.67–1.73 (m, CH ), 4.11 (q, J ¼ 7.08 Hz, CH ), 7.24–7.28 (m, ArH), 7.61–7.67
2
2
2
(
(
(
(
m, ArH), 7.85 (d, J ¼ 4.56 Hz, PyH), 7.91 (d, J ¼ 4.72 Hz, PyH), 11.05 (s, NH), 11.84 (s, NH) ppm; IR
ꢂ1
þ
KBr): ꢁꢀ ¼ 3380, 3130, 1720, 1700, 1680cm ; MS (70 eV): m=z(%) ¼ 350 (M , 6), 271 (50), 165
1
37), 141 (100), 113 (20); HRMS: calcd for C H F N O 350.1190, found 350.1199; C NMR
3
1
6 16 2 4 3
125 MHz, DMSO-d ): ꢀ ¼ 13.6, 19.3, 29.9, 51.2, 111.6, 112.7, 113.2, 135.8, 138.3, 150.3, 155.6,
6
1
57.4, 159.4, 162.8ppm.
1
-(2,6-Difluorobenzoyl)-3-(2-pentyl-3-oxopyridazin-4-yl)urea (3e, C H F N O )
1
7 18 2 4 3
ꢁ
1
Yield 66%; light yellow solid; mp 159–160 C; H NMR (500MHz, CDCl ): ꢀ ¼ 0.90 (t, J ¼ 7.02 Hz,
3
CH ), 1.32–1.38 (m, 2CH ), 1.79–1.85 (m, CH ), 4.19 (q, J ¼ 7.41 Hz, CH ), 7.01–7.04 (m, ArH),
3
2
2
2
7
.49–7.54 (m, ArH), 7.72 (d, J ¼ 4.77 Hz, PyH), 7.75 (d, J ¼ 4.61Hz, PyH), 9.19 (s, NH), 11.40 (s, NH)
ꢂ1
þ
ppm; IR (KBr): ꢁꢀ ¼ 3380, 3210, 1730, 1710, 1660 cm ; MS (70 eV): m=z(%) ¼ 364 (M , 5), 179
1
3
C
(21), 157 (22), 141 (100), 113 (23); HRMS: calcd for C H F N O 364.1347, found 364.1370;
1
7 18 2 4 3
NMR (125 MHz, DMSO-d ): ꢀ ¼ 13.8, 21.7, 27.4, 28.2, 51.7, 111.7, 112.8, 113.5, 135.7, 137.9, 150.4,
6
1
55.8, 157.2, 160.1, 162.5 ppm.